TuHURA Biosciences, Inc./NV
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
HURA$1.51-9.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six months ended | |||
|---|---|---|---|
| June 30, · June 30, | |||
| 2025 · 2024 | |||
| Cash flows from Operating activities: | |||
| Net loss | $(16,188,206) | $(10,107,377) | |
| Adjustments to reconcile net loss to cash | |||
| used in operating activities: | |||
| Stock compensation expense | 2,831,783 | 610,096 | |
| Depreciation and amortization | 27,429 | 69,934 | |
| Amortization of debt discount | - | 438,172 | |
| Change in fair value of derivative liability | - | 335,001 | |
| Changes in operating assets and liabilities: | |||
| Other current assets | 110,418 | 33,704 | |
| Other noncurrent assets | (70,380) | 87,386 | |
| Accounts payable and accrued expenses | 2,302,372 | (366,969) | |
| Net cash flows from operating activities | (10,986,584) | (8,900,053) | |
| Cash flows from investing activities: | |||
| Cash paid for business acquisition, net of cash received from Kineta | (1,259,278) | - | |
| Purchase of property and equipment | (48,233) | (36,498) | |
| Net cash flows from investing activities | (1,307,511) | (36,498) | |
| Cash flows from financing activities: | |||
| Cash dividend payment of preferred stock Series A | (4,178) | - | |
| Proceeds from warrants exercised | 3,620,657 | - | |
| Proceeds from convertible notes payable | - | 19,068,000 | |
| Payment of debt issuance costs | - | (1,091,488) | |
| Proceeds from issuance of common stock | 5,914,625 | - | |
| Payment of transaction costs related to Kintara merger | (500,000) | - | |
| Payment of deferred offering costs | (331,363) | (393,707) | |
| Payment of net liabilities assumed in reverse recapitalization with Kintara | (550,000) | - | |
| Net cash flows from financing activities | 8,149,741 | 17,582,805 | |
| Net change in cash and cash equivalents | (4,144,354) | 8,646,254 | |
| Cash and cash equivalents at the beginning of the period | 12,657,178 | 3,665,032 | |
| Cash and cash equivalents at the end of the period | $8,512,824 | $12,311,286 | |
| Supplemental non-cash activity | |||
| Due from stockholders not yet received for common stock | $2,997,548 | $ | - |
| Consideration in common shares for Kineta acquisition | 8,875,680 | - | |
| Fair value of placement agent warrants issued in connection with common stock issuance | 276,649 | - | |
| Fair value of investor warrants issued in connection with common stock issuance | 6,396,017 | - | |
| Right-of-use asset recognized in exchange for operating lease obligations | - | 318,722 | |
| Debt issuance costs not yet paid | 381,332 | 354,510 | |
| Deferred offering costs not yet paid | 45,336 | 527,249 | |
| Fair value of warrants associated with convertible notes payable | - | 4,097,193 | |
| Derivative liability associated with make-whole premium | - | 1,534,999 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.